CN1247544C - 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途 - Google Patents

带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途 Download PDF

Info

Publication number
CN1247544C
CN1247544C CNB028118502A CN02811850A CN1247544C CN 1247544 C CN1247544 C CN 1247544C CN B028118502 A CNB028118502 A CN B028118502A CN 02811850 A CN02811850 A CN 02811850A CN 1247544 C CN1247544 C CN 1247544C
Authority
CN
China
Prior art keywords
heteroaryl
carbon atom
alkyl
methyl sulphonyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028118502A
Other languages
English (en)
Chinese (zh)
Other versions
CN1529695A (zh
Inventor
J·布伦德尔
T·伯梅
S·波伊克特
H-W·克勒曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH, Aventis Pharma Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Publication of CN1529695A publication Critical patent/CN1529695A/zh
Application granted granted Critical
Publication of CN1247544C publication Critical patent/CN1247544C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB028118502A 2001-06-12 2002-05-31 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途 Expired - Fee Related CN1247544C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10128331.8 2001-06-12
DE10128331A DE10128331A1 (de) 2001-06-12 2001-06-12 Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Publications (2)

Publication Number Publication Date
CN1529695A CN1529695A (zh) 2004-09-15
CN1247544C true CN1247544C (zh) 2006-03-29

Family

ID=7687941

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028118502A Expired - Fee Related CN1247544C (zh) 2001-06-12 2002-05-31 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途

Country Status (40)

Country Link
US (2) US6903216B2 (enExample)
EP (1) EP1399423B9 (enExample)
JP (1) JP4422477B2 (enExample)
KR (1) KR100863924B1 (enExample)
CN (1) CN1247544C (enExample)
AR (1) AR036045A1 (enExample)
AT (1) ATE378318T1 (enExample)
AU (1) AU2002316939B2 (enExample)
BG (1) BG108415A (enExample)
BR (1) BR0210374A (enExample)
CA (1) CA2450076C (enExample)
CO (1) CO5540283A2 (enExample)
CR (1) CR7140A (enExample)
CY (1) CY1107427T1 (enExample)
CZ (1) CZ20033361A3 (enExample)
DE (2) DE10128331A1 (enExample)
DK (1) DK1399423T3 (enExample)
EC (1) ECSP034883A (enExample)
EE (1) EE05196B1 (enExample)
ES (1) ES2295360T3 (enExample)
HR (1) HRP20031028A2 (enExample)
HU (1) HUP0400159A3 (enExample)
IL (2) IL159247A0 (enExample)
MA (1) MA27037A1 (enExample)
MX (1) MXPA03010875A (enExample)
MY (1) MY138341A (enExample)
NO (1) NO20035450D0 (enExample)
NZ (1) NZ530081A (enExample)
OA (1) OA12631A (enExample)
PE (1) PE20021066A1 (enExample)
PL (1) PL364371A1 (enExample)
PT (1) PT1399423E (enExample)
RS (1) RS97703A (enExample)
RU (1) RU2293727C2 (enExample)
SK (1) SK15222003A3 (enExample)
TN (1) TNSN03134A1 (enExample)
TW (1) TWI304400B (enExample)
UA (1) UA75412C2 (enExample)
WO (1) WO2002100825A2 (enExample)
ZA (1) ZA200308520B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
WO2003091217A1 (en) * 2002-04-26 2003-11-06 Ishihara Sangyo Kaisha, Ltd. Pyridine compounds or salts thereof and herbicides containing the same
EP1388535A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
DE10312061A1 (de) * 2003-03-18 2004-09-30 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit Blockern des IK-Kanals und deren Verwendung zur Behandlung von Vorhofarrhythmien
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
EP1489071A1 (en) * 2003-06-18 2004-12-22 4Sc Ag N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators
CA2534887A1 (en) 2003-08-08 2005-02-24 Janssen Pharmaceutica, N.V. Process for the preparation of 2- (quinoxalin-5-ylsulfonylamino) -benzamide compounds
DE10341233A1 (de) * 2003-09-08 2005-03-24 Aventis Pharma Deutschland Gmbh Kombination von Phenylcarbonsäureamiden mit beta-Adrenozeptoren-Blockern und deren Verwendung zur Behandlung von Vorhofarrhythmien
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
GB0412986D0 (en) 2004-06-10 2004-07-14 Xention Discovery Ltd Compounds
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
WO2006036670A1 (en) * 2004-09-24 2006-04-06 Janssen Pharmaceutica, N.V. Sulfonamide compounds
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
SG163543A1 (en) * 2006-04-27 2010-08-30 Sanofi Aventis Deutschland Inhibitors of the task-1 and task-3 ion channel
WO2008124524A2 (en) * 2007-04-03 2008-10-16 Janssen Pharmaceutica N.V. Aryl sulfonamide compounds as modulators of the cck2 receptor
GB0815784D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815782D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
AR077292A1 (es) 2009-06-29 2011-08-17 Agios Pharmaceuticals Inc Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas
HRP20130485T1 (en) * 2009-06-29 2013-06-30 Merz Pharma Gmbh & Co. Kgaa Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
WO2011010132A1 (en) * 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
RU2414893C1 (ru) * 2009-11-11 2011-03-27 Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" Четвертичное аммониевое производное новокаина, обладающее противоаритмической активностью, и способ его получения
FR2967674B1 (fr) 2010-11-23 2012-12-14 Pf Medicament Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
GB201105659D0 (en) 2011-04-01 2011-05-18 Xention Ltd Compounds
NO3175985T3 (enExample) 2011-07-01 2018-04-28
AU2013203252B2 (en) 2012-01-27 2015-08-20 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
US9701627B2 (en) * 2014-06-16 2017-07-11 University Of Maryland, Baltimore LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders
JP7205830B2 (ja) * 2017-08-07 2023-01-17 国立大学法人広島大学 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ277556A (en) 1993-12-27 1997-06-24 Eisai Co Ltd N-phenyl(alkyl)- and n-pyridyl(alkyl)anthranilic acid derivatives; intermediates
US5670504A (en) 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
DK173062B1 (da) 1996-10-11 1999-12-13 Krueger As I Fremgangsmåde til fjernelse af opløste metaller og/eller metalloider fra et vandigt medium indeholdende samme og med et sto
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
JP3786579B2 (ja) 1998-07-08 2006-06-14 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 硫黄置換スルホニルアミノカルボン酸ｎ−アリールアミド、それらの製造、それらの使用、及びそれらを含む医薬製剤
WO2000012077A1 (en) 1998-09-01 2000-03-09 Bristol-Myers Squibb Company Potassium channel inhibitors and method
BR0011571A (pt) * 1999-06-24 2002-03-05 Smithkline Beecham Corp Antagonistas do receptor de limpeza de macrófago
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) * 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) * 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
ZA200308520B (en) 2004-09-06
BR0210374A (pt) 2004-07-13
DE10128331A1 (de) 2002-12-19
KR20040030668A (ko) 2004-04-09
AU2002316939B2 (en) 2006-11-23
ES2295360T3 (es) 2008-04-16
CA2450076A1 (en) 2002-12-19
TWI304400B (en) 2008-12-21
UA75412C2 (en) 2006-04-17
WO2002100825A2 (de) 2002-12-19
IL159247A (en) 2010-06-16
RS97703A (sr) 2006-12-15
MA27037A1 (fr) 2004-12-20
RU2293727C2 (ru) 2007-02-20
PL364371A1 (en) 2004-12-13
DE50211213D1 (de) 2007-12-27
ATE378318T1 (de) 2007-11-15
PE20021066A1 (es) 2003-01-21
CN1529695A (zh) 2004-09-15
IL159247A0 (en) 2004-06-01
NZ530081A (en) 2005-07-29
DK1399423T3 (da) 2008-03-17
HUP0400159A3 (en) 2008-10-28
SK15222003A3 (sk) 2004-06-08
PT1399423E (pt) 2008-02-07
JP4422477B2 (ja) 2010-02-24
EP1399423B9 (de) 2008-02-27
OA12631A (fr) 2006-06-14
RU2004100302A (ru) 2005-04-10
CY1107427T1 (el) 2012-12-19
KR100863924B1 (ko) 2008-10-17
US20030114499A1 (en) 2003-06-19
AR036045A1 (es) 2004-08-04
NO20035450D0 (no) 2003-12-08
US7235664B2 (en) 2007-06-26
EE200300558A (et) 2004-02-16
US6903216B2 (en) 2005-06-07
CZ20033361A3 (cs) 2004-05-12
JP2004533464A (ja) 2004-11-04
TNSN03134A1 (en) 2005-12-23
CA2450076C (en) 2010-11-30
EE05196B1 (et) 2009-08-17
MY138341A (en) 2009-05-29
HK1065316A1 (en) 2005-02-18
WO2002100825A3 (de) 2003-12-11
CO5540283A2 (es) 2005-07-29
MXPA03010875A (es) 2004-02-17
EP1399423A2 (de) 2004-03-24
BG108415A (en) 2004-07-30
US20050137200A1 (en) 2005-06-23
ECSP034883A (es) 2004-01-28
EP1399423B1 (de) 2007-11-14
CR7140A (es) 2004-04-15
HUP0400159A2 (hu) 2004-07-28
HRP20031028A2 (en) 2005-10-31

Similar Documents

Publication Publication Date Title
CN1247544C (zh) 带有杂芳基磺酰基侧链的邻氨基苯甲酰胺及其作为抗心律失常活性物质的用途
CN1304382C (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
CN1259307C (zh) 酰化的二氢化茚基胺及其作为药物的用途
CN1168721C (zh) 5-氰基-2-氨基嘧啶衍生物
CN1522244A (zh) 邻氨基苯甲酰胺类化合物、其制备方法、其作为抗心律不齐剂的应用及其药物制剂
CN1085663C (zh) 作为解痛剂的芳族氨基醚
CN1390196A (zh) 具有药理活性的新的二羧酸衍生物
CN1195738C (zh) 2′－取代的1,1′－联苯－2－甲酰胺、它们的制备方法、作为药物的用途和含有它们的药物制剂
CN1642927A (zh) 环状酰胺
CN1279672A (zh) 新颖的哒嗪衍生物和含有其作为有效成分的药物
CN1756746A (zh) 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
CN1608061A (zh) 治疗用的异喹啉化合物
CN1537102A (zh) 用作钾通道抑制剂的邻位取代的含氮双芳基化合物
CN1444573A (zh) 甲酰胺化合物及其作为人11cby受体拮抗剂的用途
CN1784390A (zh) 具有抗病毒性能的取代二氢喹唑啉
CN1296354C (zh) 具有药物活性的吡咯烷衍生物
CN1545509A (zh) 用作趋化因子受体活性调节剂的哌啶衍生物
CN1414849A (zh) 羧酸酰胺,包含该化合物的药物组合物,其用途及制备
CN101058564A (zh) 芳基烷基氨基甲酸酯衍生物的生产及其在治疗中的用途
CN1617856A (zh) 取代的4－苯基四氢异喹啉、其制备方法、其用作药物的用途以及含有它们的药物
CN1251577A (zh) 稠环化合物及其生产和应用
CN1671668A (zh) 4－取代芳基－5－羟基异喹啉酮衍生物
CN1599722A (zh) 作为毒蕈碱受体拮抗剂的4－哌啶基烷基胺衍生物
CN101031541A (zh) 4－氨基甲基苄脒衍生物及其作为因子Ⅷa抑制剂的用途
CN1040366A (zh) 丁烯酸或丙烯酸衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1065316

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060329

Termination date: 20150531

EXPY Termination of patent right or utility model